Postapproval Pregnancy Safety: The Final Guidance and the PSUR Architecture Problem

A Final Guidance That Changes Section 5 of Your PSUR

On May 8, 2026, the FDA finalised its guidance for industry on postapproval pregnancy safety studies. The headline is methodological: the agency is laying out which study designs are appropriate for generating safety data on drug use during pregnancy after a product is approved.

The deeper read, for regulatory writing teams, is structural. The guidance shifts what the postapproval safety section of a labelling proposal needs to commit to, and it pushes the periodic safety update into territory most teams have been navigating informally.

CDER Acting Director Tracy Beth Hoeg framed the problem in her quote on the announcement:

"Currently many medical products may be recommended to pregnant women by healthcare providers in spite of the fact that data from the clinical trials used for FDA approval were insufficient to assess safety during pregnancy."

That gap has existed for as long as drug development has excluded pregnant populations from registrational trials, which is to say, effectively always. The new guidance does not change that exclusion. What it changes is the expectation for how that gap is filled after approval.

What the Guidance Actually Says

The final guidance describes three categories of postapproval pregnancy safety study designs and the conditions under which each is appropriate.

Pregnancy registries. The most familiar category. Prospective enrolment of pregnant women exposed to the product, with structured follow-up through delivery and beyond. The guidance is clear that registries are appropriate when the product has, or is expected to have, meaningful use in women of reproductive age, when exposure during pregnancy is plausible, and when the safety signal is not already well-characterised. Registry design considerations — sample size justification, comparator selection, outcome definitions — get specific treatment.

Real-world data and observational studies. Cohort studies and case-control designs using insurance claims, electronic health records, or other RWD sources. The guidance addresses methodological best practices for observational research in this setting, particularly around confounding, exposure misclassification, and outcome definition.

Descriptive case-report studies. The bottom rung of the evidence hierarchy, but explicitly endorsed where the exposure or condition is rare enough that systematic approaches are infeasible. The guidance is more cautious here, noting that case reports inform hypothesis generation rather than risk characterisation.

The guidance also discusses how these three approaches should be combined — when a registry should be complemented by an RWD study, when case reports should trigger a more structured follow-up.

Why This Lands in the PSUR

The Periodic Safety Update Report is where postapproval safety information is summarised and presented to the agency on a regular cadence. The Section 5 (Studies in Special Populations) and Section 16 (Special Risk Groups) elements of a typical PSUR are where pregnancy-related safety data has historically lived.

The new guidance reshapes that content in three ways.

Methodological transparency becomes mandatory. The PSUR has always required summaries of postapproval studies. The guidance pushes the bar higher: methodological choices, particularly for observational research, need to be described in enough detail that the agency can assess whether the design is fit for purpose. Sponsors that previously summarised a pregnancy registry as "ongoing, with N exposures" now need to describe the registry's design, comparator strategy, and outcome adjudication.

Cross-study integration becomes the expectation. When a sponsor is running a registry, an RWD complementary study, and aggregating case reports, the PSUR needs to integrate the findings across all three. Discrepancies between sources need to be addressed. Convergent signals need to be highlighted. The agency does not want three separate methodological narratives — it wants an integrated postapproval pregnancy safety case.

Labelling implications need to be tracked explicitly. The guidance is clear that the goal of postapproval pregnancy safety data is to inform labelling so clinicians and patients can make informed decisions. The PSUR's labelling impact discussion needs to address whether the accumulating safety data supports a labelling update, supports the current labelling, or raises questions that warrant further investigation.

The Cross-Document Consistency Problem Gets Worse

For regulatory writing teams operating on multi-product portfolios, the guidance creates a coordination problem that the previous draft did not explicitly surface.

Pregnancy safety language appears in at least four document types: the package insert (specifically Section 8.1, the Pregnancy subsection), the risk management plan or REMS where one applies, the PSUR, and the postapproval study protocols themselves. Each of these is drafted by a different sub-function of the regulatory writing team, often on a different cadence, sometimes with different source data freshness.

The guidance does not require these to be perfectly synchronised at all times. But the agency now has a clearer expectation that they are coordinated, particularly when a labelling update is being proposed based on accumulating safety data.

For writing teams operating with traditional document-stitching workflows, this is a high-friction coordination problem. For teams operating with modern document tooling that knows which sections reference shared data sources, it is a high-leverage place to invest in cross-document consistency checks before any of these documents go to the agency.

What to Update This Quarter

For regulatory operations teams with active postapproval safety programs that touch pregnancy data, three practical updates are worth making this quarter.

Review your active pregnancy registries against the guidance. Where the registry's design diverges from the guidance's recommendations, document the rationale. Where the registry can be brought into closer alignment without compromising its primary objectives, update the protocol.

Audit your PSUR templates. The Section 5 and Section 16 content for any product with a pregnancy registry, an RWD complementary study, or accumulating case reports needs a structural review. Confirm that methodological descriptions are detailed enough, cross-study integration is explicit, and labelling implications are addressed.

Brief your medical writers and pharmacovigilance leads on the guidance specifics. The methodological vocabulary in the final guidance is precise. Writers and PV staff need to use the same terms the agency uses, particularly when describing observational study design choices.

The guidance does not create legally enforceable requirements. It describes the agency's current thinking. In practice, the agency's current thinking is what regulatory writing teams have to write to. That work starts now.